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Abstract
Alzheimer’s disease is characterized by the presence of aggregates of amyloid beta (Ab) in senile plaques and tau in neurofibril-
lary tangles, as well as marked neuron and synapse loss. Of these pathological changes, synapse loss correlates most strongly
with cognitive decline. Synapse loss occurs prominently around plaques due to accumulations of oligomeric Ab. Recent evidence
suggests that tau may also play a role in synapse loss but the interactions of Ab and tau in synapse loss remain to be deter-
mined. In this study, we generated a novel transgenic mouse line, the APP/PS1/rTg21221 line, by crossing APP/PS1 mice, which
develop Ab-plaques and synapse loss, with rTg21221 mice, which overexpress wild-type human tau. When compared to the
APP/PS1 mice without human tau, the cross-sectional area of ThioS+ dense core plaques was increased by ~50%. Along with
increased plaque size, we observed an increase in plaque-associated dystrophic neurites containing misfolded tau, but there was
no exacerbation of neurite curvature or local neuron loss around plaques. Array tomography analysis similarly revealed no wors-
ening of synapse loss around plaques, and no change in the accumulation of Ab at synapses. Together, these results indicate
that adding human wild-type tau exacerbates plaque pathology and neurite deformation but does not exacerbate plaque-asso-
ciated synapse loss.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease
that is the most common cause of dementia in the elderly. It is char-
acterized neuropathologically by the aggregation of amyloid beta
(Ab) into senile plaques and tau into neuroﬁbrillary tangles (NFTs),
as well as by pronounced synapse loss, neuron loss and gliosis
(Duyckaerts et al., 2009).
The amyloid cascade hypothesis of disease pathogenesis posits
that AD is initiated by the accumulation of Ab, which then leads to
glial-, neuronal- and tau-related neuropathological hallmarks (Hardy
& Higgins, 1992). This hypothesis is strongly supported by the
genetics of familial early onset AD, which is caused by mutations in
the proteins that are essential for the generation of Ab: amyloid pre-
cursor protein (APP), presenilin-1 (PS1) and presenilin-2 (PS2;
Tanzi, 2012). The accumulation of Ab plaques correlates less well
with cognitive decline in AD than NFTs (Ingelsson et al., 2004),
although mutations in the tau gene, Mapt, cause fronto-temporal
dementia (FTD) but not AD (Hutton, 2000). However, neither pla-
ques nor tangles correlate as well with cognitive decline as synapse
loss, emphasizing the important role of synapse toxicity for patho-
genesis and disease progression in AD (Spires-Jones & Hyman,
2014).
Animal models and human studies have shown that soluble oligo-
mers of both Ab- and FTD-associated mutant tau contribute to
synapse loss (Walsh et al., 2002; Shankar et al., 2008; Kofﬁe et al.,
2009, 2012; Kopeikina et al., 2011; Lasagna-Reeves et al., 2011;
Bilousova et al., 2016). When expressed in the same animal model,
these small pathological molecules can affect the distribution and
pathology of each other (Oddo et al., 2003; Pooler et al., 2015).
Modulation of one of the pathologies often affects the other in these
models, strongly indicating that these processes are interconnected
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(Oddo et al., 2006; Castillo-Carranza et al., 2015) but the molecular
pathways linking Ab, tau, and synapse degeneration remain largely
unknown.
There is strong evidence that tau is necessary for Ab-mediated
synaptic pathology in animal models of plaque deposition. Geneti-
cally reducing endogenous tau is protective against synaptic pheno-
types including LTP deﬁcits, seizures, and axonal transport deﬁcits
(Roberson et al., 2007, 2011; Shipton et al., 2011; Vossel et al.,
2015). However, there are alternative hypotheses stipulating that
tau and Ab pathologies start independently but then act synergisti-
cally to cause synapse loss and cognitive decline (Small & Duff,
2008).
In this study, we examine Ab-plaque load and synapse loss in
the presence of human tau. We generate a mouse model (APP/
PS1/rTg21221) of early AD, in which mutant human APP, PS1,
and wild-type human tau are co-expressed. This novel mouse line
allows analysis of interactions of human tau and Ab in a mam-
malian brain with age-related pathology (which cannot be fully
recapitulated in vitro). APP/PS1 mice expressing both mutant APP
and PS1 (but no human tau) show plaque deposition at 4–
6 months of age (Jankowsky et al., 2004). Cognitive impairments,
synapse loss around plaques (Kofﬁe et al., 2009) and disruption of
Ca2+ regulation in dendritic spines are well-established phenotypes
of this line (Wu et al., 2010). In contrast, rTg21221 mice that
overexpress wild-type human tau (hTau) show only slight behav-
ioral phenotypes and tau hyperphosphorylation, no tau aggregation
into NFTs, and no synapse loss (Hoover et al., 2010). By crossing
these two lines, we tested the synergy between Ab and tau, how
tau contributes to Ab-related pathology, and how Ab effects non-
mutant tau.
We hypothesized that increasing the amount of tau in a mouse
model of AD would worsen synapse loss. However, surprisingly,
we found that while over-expressing wild-type human tau increases
Ab-plaque size and dystrophic neurite number, it does not exacer-
bate Ab-mediated synapse loss, neuron loss or gliosis.
Materials and methods
Generation of App/PS1/rTg21221 mice
B6.C3 APP/PS1 mice (stock #004462, Jackson Laboratories Bar
Harbor, ME), which express APPswe and PS1Dexon9 (Jankowsky
et al., 2004), were crossed with B6.129-Tg(CK-tTA) mice that
express the tet transactivator, CK-tTA, under the control of the cal-
cium calmodulin kinase 2 alpha (CamK2a) promoter. Offspring
positive for both the APP/PS1 and CK-tTA transgene were then
crossed to transgene homozygous Tg(tetO-HuTauwt) 21221 mice
(Hoover et al., 2010). Expression of human wild-type human 4-
repeat tau in rTg21221 mice is under the control of a dox-off tetra-
cycline transactivator responsive promoter. Mice positive for the
APP/PS1, CK-tTA and rTg21221 transgenes (APP/PS1/rTg21221)
overexpress APPswe and PS1Dexon9 as well as wild-type human tau
in the forebrain.
Mice used were 8–10 months old and of mixed sex. Animals were
group housed, and had ad libitum access to food and water. Animals
were killed with CO2 and brains collected. Brain hemispheres were
ﬁxed for 48 h in 4% paraformaldehyde (PFA) in PBS, cryoprotected
in 15% glycerol in PBS, then frozen in dry ice and sectioned into
50 lm thick coronal sections using a freezing microtome (Leica
2010R). From the other hemisphere, small samples of somatosensory
cortex (1 9 1 9 5 mm3) were dissected freshly from each brain for
array tomography, and the remainder brain tissue was ﬂash-frozen at
80 °C for biochemical analyses. The number of animals used in
each experiment can be found in the ﬁgure legend for that experi-
ment. All animal experiments conformed to national and institutional
guidelines including the Animals [Scientiﬁc Procedures Act] 1986
(UK), and the Council Directive 2010/63EU of the European Parlia-
ment and the Council of 22 September 2010 on the protection of ani-
mals used for scientiﬁc purposes, and had full IACUC and Home
Ofﬁce ethical approval.
Synaptoneurosome preparation
Synaptoneurosomes and crude homogenate were prepared as
described previously (Tai et al., 2012). In brief, < 100 mg of frozen
murine frontal cortex was homogenized in 700 lL of ice-cold buffer
A (25 mmol/L HEPES pH 7.5, 120 mmol/L NaCl, 5 mmol/L KCl,
1 mmol/L MgCl2 and 2 mmol/L CaCl2), supplemented with
2 mmol/L di-thiothreitol, protease inhibitors (Roche complete mini)
and phosphatase inhibitors. The homogenate was passed through
two layers of 80-lm nylon ﬁlters (Millipore, Watford, UK), and a
200 lL aliquot of the ﬁltered homogenate was saved. The saved ali-
quot was mixed with 200 lL water and 70 lL 10% SDS, to prepare
the crude homogenate.
To prepare synaptoneurosomes, the remainder of the homogenate
was passed through a 5-lm Durapor membrane ﬁlter (Millipore) to
remove large organelles and nuclei and centrifuged at 1000 g for
5 min. The non-synaptic supernatant containing cytoplasmic proteins
was removed, and the pellet was washed once with buffer A and
centrifuged again, yielding the synaptoneurosome pellet. The synap-
toneurosome pellet was suspended in 400 lL of Buffer B
(50 mmol/L Tris [pH 7.5], 1.5% SDS, and 2 mmol/L DTT) and
boiled for 5 min. Protein concentrations were determined using a
BSA assay (Thermo Fisher, Renfrew, UK).
Western blotting
Five microgram of protein from either isolated synaptoneurosomes
or crude homogenate was loaded onto NuPAGE 4–12% Bis-Tris
precast polyacrylamide 15 well gels (Invitrogen, Paisley, UK) along
with molecular weight marker (Li-Cor, Cambridge, UK). Proteins
were electro-transferred to nitrocellulose membrane (Bio-Rad, Hemel
Hempstead, UK). Membranes probed with the following primary
antibodies: Ab(82E1,IBL,1 : 100), Tau13 (MMS-520R-500, Cov-
ance, 1 : 2000), b-actin (ab8226, Abcam, 1 : 2000), Synaptophysin
(AB8049, Abcam, 1 : 10 000), a-tubulin (ab4074, Abcam,
1 : 1000), GFAP (0334, DakoCytomation, 1 : 500), GAPDH
(ab8245, Abcam, 1 : 2000). Proteins were visualized on an ODYSSEY
infrared system using the appropriate 680 and 800 IR dye secondary
antibodies (1 : 50 000, LI-COR Biosciences) and were analyzed
using ODYSSEY software (LI-COR Biosciences).
ELISA
Ab42 concentration was quantiﬁed, in isolated synaptoneurosomes,
using a colorimetric Ab42 ELISA kit (Wako, Japan) as previously
described with minor modiﬁcations (Ramos-Rodriguez et al., 2016).
Brieﬂy, 5 lL of synaptoneurosomes were diluted in 50 lL of lysis
buffer with inhibitor cocktail (Thermo Scientiﬁc Pierce, Spain).
Samples were loaded and standard curves were completed with
human Ab42 provided in the kit. Absorbance was measured spec-
trophotometrically at 450 nm (MQX200R2, Biotekinstruments,
Burlington VT, USA) and data were expressed as pMol Ab42/mg
synaptoneurosome protein.
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Immunohistochemical analyses of plaque load, neuron loss,
gliosis and neurite damage
To quantify plaque-associated neuron loss, a series of every 10th
coronal section through the brain hemisphere was stained with
0.05% Thioﬂavin-S (ThioS) in 50% ethanol for 8 min to label
dense-core plaques and NFTs and washed in 80% ethanol for 30 s.
Sections were then permeabilized for 10 min in 0.1% Triton X-100
in TBS, washed twice for 5 min in TBS, then incubated in
NeuroTrace red ﬂuorescent Nissl stain (1 : 500; Molecular Probes,
Inc.) for 1 h at room temperature to label neurons. Sections were
mounted onto superfrost plus slides using Immuno-Mount mounting
media and a cover slip was placed on top. Another series of sections
were stained with primary antibody against glial-ﬁbrillary acidic pro-
tein (GFAP; 1 : 1000, Dako Cytomation 0334) to stain for reactive
astrocytes and the Alexa Fluor conjugated secondary antibody don-
key anti-rabbit 647 (1 : 200; Life Technologies, Carlsbad, CA).
Fig. 1. Overexpression of human tau increases the cross-sectional area of ThioS-positive plaques but not the overall plaque burden. Representative images of
dense Ab-plaques (ThioS, yellow) and total Ab (AW7, red) in brain sections were used to measure plaque characteristics (A). Higher resolution images demon-
strate the halo of soluble Ab (white arrows) surrounding dense plaques in APP/PS1/rTg21221 mice and APP/PS1 mice (B). The mean cross-sectional area of
individual ThioS-positive plaques increased in APP/PS1/rTg21221 compared to APP/PS1 mice (*t-test, df = 6, P = 0.03) (C). ELISA on crude brain homoge-
nates showed a signiﬁcant increase (*t-test df = 8.673, P = 0.023) in the amount of Ab42 in APP/PS1/rTg21221 mice (D). The percentage area of cortex occu-
pied by plaques (plaque burden) was unchanged (E) as was the thickness of the soluble Ab halo around dense plaques (F). APP/PS1/rTg21221 n = 5, APP/
PS1n = 3, scale bars represent 500 lm in (A) and 20 lm in (B).
© 2016 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
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Sections were counterstained with ThioS and mounted onto slides as
described above.
Low-resolution tile scan images of every other section in the
series (coronal sections 1 mm apart) were taken at 59 magniﬁca-
tion with an epiﬂuorescence microscope (Zeiss Axio Imager Z2;
Carl Zeiss, Ltd., Cambridge, UK). Cortical thickness was measured
at three equi-distant points on each section. The cortex was out-
lined and 6–10 plaques in each section were randomly chosen and
imaged at 639 magniﬁcation (1.4 NA plan apochromat objective)
using the AXIOVISION REL. 4.8.2 software to take a z-stack through
each section at every 3 lm thickness. Neuronal numbers in the
vicinity of dense-core plaques (in a 30 9 30 9 50 lm volume)
and far from plaques (at least 100 lm in a 30 9 30 9 50 lm vol-
ume in the same cortical layer) were obtained by stereological
sampling using STEROINVESTIGATOR software. Plaque burden (the per-
centage of cortex occupied by plaques) and individual plaque area
were measured in IMAGE J. For astrocyte counts, the same sampling
scheme was used on GFAP stained sections to choose plaques on
low-resolution images and take high-resolution images of 6–10 pla-
ques per section on every 20th section. GFAP-positive astrocytes
around dense-core plaques were counted in a 30-lm radius circle
from the edge of the plaque.
To label dystrophic neurites and axons, Alz50 (kind gift of Peter
Davies) and Smi312 (ab24574, Abcam) were used at concentrations
of 1 : 1000 and 1 : 5000, respectively. Alz50-positive neurites
within the area of the ThioS-positive plaques were counted. Neurite
curvature was calculated by measuring the length of each axon seg-
ment and dividing it by the end-to-end distance of the segment.
Neurite distance from a plaque was calculated by taking an average
of the distance to the plaque from each end and the middle of the
axon segment measured. Axons were only measured if they could
be followed up for more than 20 lm and in total, 339 axons from






Fig. 2. Overexpressing human tau does not affect plaque-associated neuron loss and astrogliosis in APP/PS1 mice. Representative images of neurons (red, Neu-
rotrace stained; A,B) and GFAP-positive astroglia (red; C,D) and ThioS-positive plaques (green) in APP/PS1 (A,C) and APP/PS1/rTg21221 (B,D) mice. Neu-
rons were counted in a 30 9 30 lm box for areas near (< 30 lm) and far (> 100 lm) from plaques and as expected there was a decrease in neuronal density
in the immediate vicinity of plaques (*two-way ANOVA F1,12 = 6.852, p = 0.022). No difference was seen between genotypes (E). GFAP-positive astrocytes
counted in a radius of 30 lm around ThioS-positive plaques showed no difference either (F). APP/PS1/rTg21221 n = 5, APP/PS1n = 3, scale bar is 30 lm.
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Array tomography
Brain tissue from somatosensory cortex was prepared for array
tomography as described previously (Micheva & Smith, 2007; Kay
et al., 2013). In brief, tissue from ﬁve APP/PS1/rTg21221 and six
APP/PS1 mice was embedded in acrylic resin and cut into ribbons
of 70 nm sections that were collected on gelatin-coated glass cover-
slips. The ribbons were then stained with antibodies and imaged
along the ribbon. The ribbons were then stripped (0.2 M NaOH,
0.02%SDS in dH2O) and reprobed with a second set of antibodies
and images were taken in the same location as those on day 1.
Primary antibodies on day 1 were 1C22 [1 : 50, kind gift of
Dominic Walsh (Yang et al., 2015)], rabbit anti-synapsin-1
(1 : 100, AB1543P, Millipore) and goat anti-PSD95 (1 : 50,
ab12093, Abcam). Primary antibodies used on day 2 were AW7
(1 : 1000, kind gift of Dominic Walsh), mouse anti-Tau13 (1 : 50,
MMS-520R-500, Covance) and goat anti-PSD95 (1 : 50, ab12093,
Abcam). 1C22 recognizes conformer speciﬁc oligomeric Ab and
was raised in a mouse and AW7 recognizes total Ab and was raised
in a rabbit. Secondary antibodies were purchased from Invitrogen
and were used at 1 : 50. Alexa Fluor conjugated secondary antibod-
ies used on day 1 were donkey anti-mouse 488 (A21202), donkey
anti-rabbit 594 (A21207) and donkey anti-goat 647 (A21447). Sec-
ondary antibodies used on day 2 were donkey anti-mouse 488
(A21202), donkey anti-rabbit 647 (A31573) and donkey anti-goat
594 (A11058).
Images from each section in the ribbon were complied to create a
3D stack and aligned using IMAGEJ multistackreg macros (Thevenaz
et al., 1998). Regions of interest (10 9 10 lm) were selected near
plaques (< 20 lm) and far from plaques (> 40 lm). Images were
thresholded in IMAGEJ/FIJI (Schindelin et al., 2012) and custom
MATLAB macros were used to remove single slice punctate, count
synaptic punctuate and assess co-localization with 1C22 (all
custom analysis macros will be freely available along with data
spreadsheets supporting this manuscript at http://dx.doi.org/10.7488/
ds/1507).
Statistics
In these experiments, we compare APP/PS1 mice to APP/PS1/
rTg21221 mice with the experimental unit being a single animal.
Numbers of animals in each experiment are shown in ﬁgure legends.
For each parameter, a mean or median (depending on normality)
was calculated for each animal, and then the group mean or median
was calculated. The null hypothesis was no difference between
APP/PS1 and APP/PS1/rTg21221 mice for each measured parame-
ter. Statistical analysis on the data obtained was performed using
SPSS software (version 21 IBM Armonk, New York, USA). Each
data set was individually tested for normal distribution using the
Shapiro–Wilk normality test. When data were normally distributed
such as the astrocytes quantiﬁcation around plaques, ANOVA or Stu-
dents T-test was used to test for difference between the means for
Fig. 3. Overexpression of human tau exacerbates plaque-associated dystrophic neurites but does not affect neurite curvature. Staining of cortical sections neu-
rites (smi312, red), misfolded tau (Alz50, blue), and plaques (ThioS, green) shows the accumulation of tau-positive dystrophic neurites and the abnormal curva-
ture of neurites near plaques in both APP/PS1 and APP/PS1/rTg21221 mice (A). Neurite curvature was measured by dividing the length (solid line) by the end-
to-end distance (dotted line) of each neurite segment (B). Quantiﬁcation reveals an increase in Alz50-positive dystrophic neurites around plaques in APP/PS1/
rTg21221 mice (C) (*t-test df = 0.047, P = 0.047), whereas the neurite curvature does not change in presence of human tau (D). APP/PS1/rTg21221 n = 5,
APP/PS1 n = 3, scale bars are 10 lm (A) and 3 lm (B).
© 2016 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
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each individual animal data across the experimental conditions.
Tukey’s post hoc multiple comparisons test was also applied. When
data were not normally distributed, such as the neuronal and micro-
glial counts as well as the quantiﬁcation of the western blot data, a
non-parametric Kruskal–Wallis test was used to test for signiﬁcant
difference between the medians for each individual animal across
the experimental groups. All statistics were carried out at 95% conﬁ-
dence intervals, therefore a signiﬁcant threshold of P < 0.05 was
used in all analyses; the number of mice used in each experiment
can be found in the ﬁgure legends.
Fig. 4. Overexpression of human tau does not cause tangle formation or increase tau hyperphosphorylation. PHF1 positive tau accumulates in neuropil threads
in APP/PS1/rTg21221 mice (A) and in dystrophic neurites in both APP/PS1/rTg21221 (B) and APP/PS1 mice (C). A western blot of crude homogenate from
the cortex of a mouse (5 lg protein) was probed for PHF1 (D) and GAPDH (E) as a loading control. The PHF1 bands between 55–65 kDa were quantiﬁed and
the overexpression of human tau did not change the overall levels of PHF1 (F). APP/PS1/rTg21221 n = 6, APP/PS1n = 3, rTg21221 n = 4 Scale bar 5 lm.
© 2016 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
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Results
Effects of hTau overexpression on pathology in APP/PS1
mice
Raw analysed data from this manuscript and custom analysis macros
used in analysis are available at http://dx.doi.org/10.7488/ds/1507.
APP/PS1 mice begin to develop amyloid plaques at around 4–
6 months of age (Garcia-Alloza et al., 2006b). To determine
whether hTau overexpression affects plaque deposition in these 8–
10-month-old animals, Thioﬂavin-S (ThioS) was used to stain dense
plaques, and AW7 was used to immunolabel all Ab depositions.
Cortical ThioS-positive plaque burden was unchanged with hTau
overexpression (0.21  0.16% in APP/PS1/rTg21221 mice;
0.17  0.06% in APP/PS1 mice without hTau), as was the burden
of total Abplaques immunostained with AW7 (0.55  0.42% in
APP/PS1/rTg21221 mice; 0.39  0.05% in APP/PS1 mice,
Fig. 1E). The variability in plaque burden in the mice overexpress-
ing human tau was very high, and we did observe a signiﬁcant
increase (df = 6, P = 0.03, t-test) in the size (the average cross-sec-
tional area of plaques) of ThioS-positive plaques in APP/PS1/
rTg21221 (Fig. 1C). There was no difference in AW7-positive pla-
que size or the diameter of the halo of Ab around dense plaques.
Consistent with larger dense plaques detected with histology, we
observed an increase in Ab42 levels in brain homogenates by
ELISA in APP/PS1/rTg21221 (Fig. 1D; 4.6 pmol Ab42/mg protein)
compared to APP/PS1 mice (2.1 pmol Ab42/mg protein, df = 8.673
P = 0.023 Kruskal–Wallis test).
Neuronal loss is one of the key neuropathological hallmarks of
Alzheimer’s disease. In plaque-bearing mice, there is generally not
much overt neuronal loss without overexpressing FTD mutant tau.
Subtle plaque-associated neuron loss has been reported for APP/PS1
mice (Rupp et al., 2011). We assessed the impact of human tau
overexpression on plaque-associated neuronal loss. As described
previously, we observed subtle neuronal loss near plaques (two-way
ANOVA F1,12 = 6.852, P = 0.022 for regions near plaques vs. far
from plaques). We did not see any exacerbation of plaque-associated
neuronal loss in APP/PS1/rTg21221 mice (two-way ANOVA,
P > 0.05 for genotype and genotype 9 plaque distance interaction,
Fig. 2).
Plaque deposition is associated with local gliosis and degenerative
changes in neurites including dystrophic swellings that accumulate
pathological forms of tau (McLellan et al., 2003; Spires et al.,
2005). To examine whether human tau overexpression affects glio-
sis, activated astrocytes (GFAP-positive) within 30 lm of a plaque
were counted in APP/PS1/rTg21221 and APP/PS1 mice (Fig. 2). No
change in the number of activated astrocytes per plaque was
detected (Student T-Test P > 0.05), and quantitative western blot of
cortical homogenates conﬁrmed no global change in the amount of
GFAP (Fig. S1).
Staining of brain sections with ThioS, PHF1 and Alz50 did not
show neuroﬁbrillary tangles for either genotype (Fig. 1 for ThioS,
Fig. 3 for Alz50 and Fig. 4 for PHF1;). However, Alz50-positive
and PHF1-positive tau accumulations were observed in dystrophic
neurites around plaques (Figs 3 and 4). To examine the toxic effect
Fig. 5. Overexpression of human tau does not increase synapse loss in APP/PS1 mice. To investigate synapse loss, array tomography ribbons from APP/PS1
(n = 6) and APP/PS1/rTg21221 mice (n = 5) were stained for oligomeric Ab (oAb; 1C22), human tau (Tau13), post-synapses (PSD95), and pre-synapses (sy-
napsin-1) (A). There was synapse loss in both genotypes within 20 lm of plaques (*PSD data effect of plaque distance F1,21 = 8.4, P = 0.01; synapsin data
*F1.21 = 16.6, P = 0.001). There is no exacerbation of synapse loss with expression of human tau of either post-synaptic terminals (B) or pre-synaptic terminals
(C) (two-way ANOVA effect of genotype F < 0.5, P > 0.05). Scale bar is 10 lm.
© 2016 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
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of Ab and hTau on neurites around plaques, brain sections were co-
immunostained for misfolded tau (Alz50) and neuroﬁlaments
(smi312), and dystrophic Alz50-positive neurite swellings (diame-
ter > 2.5 lm) associated plaques were counted (Fig. 3A). With
overexpression of human tau, there was a signiﬁcant increase in dys-
trophies per plaque (df = 6, P = 0.036 Student’s T-Test, Fig. 3C).
Curvature of smi312-positive neurites, which is known to increase
around Ab-plaques (Garcia-Alloza et al., 2006a), was not signiﬁ-
cantly altered in APP/PS1/rTg21221 compared to APP/PS1 mice
(P > 0.05 Mann–Whitney U test, Fig. 3D). PHF1 staining also
showed an absence of tangles but the presence of dystrophic neu-
rites and neuropil threads in APP/PS1/rTg21221 mice. APP/PS1
mice without human tau also demonstrated plaque-associated PHF1-
positive neuritic dystrophies but qualitatively less neuropil threads
far from plaques (Fig. 4). Western blot analysis indicated that there
is a trend toward change (ANOVA F2,12 = 3.614, P = 0.066) in the
amount of phosphorylated tau in APP/PS1/rTG21221 compared with
APP/PS1 alone or when compared with rTG21221 mice with no
APP/PS1 (Fig. 4).
Together, these histologic data indicate an increase in amyloid
deposition and exacerbation of neuritic dystrophies around plaques
with the overexpression of human tau in APP/PS1 mice; in the
absence of neuroﬁbrillary tangle pathology.
No effect of hTau overexpression on Ab-mediated synaptic
loss
To determine if the overexpression of wild-type human tau
increased Ab-induced synaptic loss, array tomography was used to
quantify synapse density in the neocortex. Tissue ribbons were
stained for oligomeric Ab using the conformer-speciﬁc 1C22 anti-
body. A total of 126 210 synapses in APP/PS1 (n = 6 animals)
and 139 412 synapses in APP/PS1/rTg21221 mice (n = 5 animals)
were analyzed. No change in synapse density was seen for either
the pre-synaptic marker synapsin-1 or the post-synaptic marker
PSD95 (Fig. 5). However, both APP/PS1 and APP/PS1/rTg21221
mice showed a signiﬁcant decrease in the densities of pre- and
post-synapses near plaques (< 20 lm from plaque border) com-
pared to distant from plaques (> 40 lm from plaque border), simi-
lar to what has been reported previously (Kofﬁe et al., 2009).
Western blot analysis of the pre-synaptic marker synaptophysin in
crude cortical homogenates also suggested no change in synaptic
Fig. 6. Overexpression of human tau does not affect the localization of Ab at synapses. Analysis of the co-localization of Ab labeled with 1C22 and PSD95
or synapsin-1 (A) show that Ab presence at pre-synapses (B) or post-synapses (C) does not change when human tau is overexpressed in APP/PS1/rTg21221
mice (two-way ANOVA effect of genotype F < 0.3, P > 0.05). In both pre and post synapses, there is a signiﬁcantly higher percentage of synapses containing
Ab near plaques vs. far from plaques (PSD data effect of plaque distance *F1,21 = 363.6, P = 2.19 9 10
13; synapsin data *F1,21 = 13.3, P = 0.002). APP/
PS1/rTg21221 n = 5, APP/PS1 n = 6, scale bar is 10 lm, scale bar for insert is 2 lm.
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protein levels between APP/PS1 and APP/PS1/rTg21221 mice
(Fig. S2).
As there is evidence that the accumulation of Ab at synapses
contributes to synaptic shrinkage and loss (Kofﬁe et al., 2009), we
next assessed the co-localization of synaptic markers with the
oligomeric Ab antibody 1C22 (Fig. 6). While both genotypes had
signiﬁcantly more Ab at synapse near plaques than far from pla-
ques, the overexpression of human tau did not increase the amount
of Ab found co-localized with the synapse. This ﬁnding was con-
ﬁrmed biochemically by assaying synaptoneurosome preparations
using a human Ab ELISA (Fig. S3A), and by western blot analysis
of the same preparations using Ab antibody (82E1; Fig. S3B and
C); both assays showed no difference between mice APP/PS1 and
APP/PS1/rTg21221 mice. Furthermore, the presence of Ab in APP/
PS1/rTg21221 mice did not increase the amount of human tau
found in synaptoneurosomes compared to rTg21221 mice (Fig. S3D
and E).
Discussion
From genetic data, it is clear that changes in APP processing, lead-
ing to increased Ab42 levels, initiate the disease process in familial
AD (fAD), and likely also in sporadic AD (Hardy & Selkoe, 2002).
It is also clear that pathological changes in tau correlate better than
plaque deposition with neuronal death observed in AD (Gomez-Isla
et al., 1997). However, the connection between Ab and tau patholo-
gies remains enigmatic and it is still unknown how changes in amy-
loid processing can cause neurotoxicity related to tau.
The synergistic effects of Ab and tau in the deposition of the
classic pathological lesions – plaques and neuroﬁbrillary tangles –
have been modeled in mice expressing fAD mutant APP and FTD
mutant tau, such as the 39Tg line (Oddo et al., 2003), which devel-
ops both pathologies. In these mice, amyloid deposition precedes
tau deposition, and the removal of Ab by immunotherapy also
reduces early tau pathology (phospho-tau) but tangles remain
unchanged (Oddo et al., 2004). However, immunotherapies directed
against tau do not affect Ab, indicating a role for Ab upstream of
tau pathology (Walls et al., 2014). Recently, we generated mouse
model that expresses brain-wide human mutant APP and human
mutant P301L tau only in the entorhinal cortex by crossing APP/
PS1 mice with rTgTauEC mice (Pooler et al., 2015). In these mice,
the presence of human Ab accelerates tau propagation through the
brain and increases plaque size and plaque-associated dystrophic
neurites. Together, these studies support the idea of an interaction
between plaques and tangles, at least in the presence of disease-
associated mutations in both Ab and tau. In contrast, at the rela-
tively young age we examined in our focus on synapse loss, we did
not observe neuroﬁbrillary tangles in APP/PS1 mice overexpressing
wild-type human tau (APP/PS1/rTg21221), however, we found lar-
ger plaques and exacerbated dystrophic neurites, similar to our pre-
vious observations in APP/PS1xrTgTauEC mice (Pooler et al.,
2015). A recent study found that mice with high levels of human
Ab oligomers do develop neuroﬁbrillary tangle pathology at much
older ages (18 months) when crossed with wild-type human tau
expressing mice (Umeda et al., 2014). This is likely due to the dif-
ferent ages examined (as here we focus on earlier synaptic changes)
but could also be due to the different forms of APP and tau
expressed in the two lines.
Synapse loss is the strongest pathological correlate of dementia
(DeKosky & Scheff, 1990; Terry et al., 1991), and is thought to be
the key pathogenic process driving AD symptoms (Spires-Jones &
Hyman, 2014). Synaptic degeneration downstream of oligomeric Ab
has been very well established not only in animal models of the dis-
ease (Walsh et al., 2002), but also in several studies of human
brains (Kofﬁe et al., 2012; Perez-Nievas et al., 2013; Bilousova
et al., 2016). Animal models of FTD expressing mutant human tau
also exhibit synaptic loss and dysfunction, along with pronounced
neurodegeneration (Rocher et al., 2010; Crimins et al., 2013;
Menkes-Caspi et al., 2015). From these data, it became clear that
pathological changes in both can independently drive synapse loss,
but it is unclear whether Ab and tau act on the same pathway to
synapse degeneration.
When plaque-bearing mice are crossed onto a mouse tau knock-
out strain (Mapt0/0), the Ab-induced synaptic phenotypes – includ-
ing seizures and LTP deﬁcits – become ameliorated. The removal
of tau was also found to be protective against memory loss associ-
ated with Ab expression in mice, likely due to protection against
synapse loss (Roberson et al., 2007, 2011; Shipton et al., 2011).
These ﬁndings provided evidence for the synergistic action of Ab
and tau toward synapse dysfunction. Here, we directly tested
whether overexpression of wild-type human tau exacerbates synaptic
loss associated with Ab-plaques. Surprisingly, the increased level of
non-mutant tau in APP/PS1/rTg21221 mice did not worsen the
synapse pathology related to Ab. Together with the Mapt0/0 data,
this indicates that the endogenous mouse tau is sufﬁcient to cause
the negative effects associated with Ab, and that there is a ceiling
effect of the requirement of tau for Ab-mediated synapse toxicity.
Indeed, it has been shown that the knock-out of endogenous mouse
tau reduces the neurotoxicity of overexpressed human mutant
P301L tau (Wegmann et al., 2015). However, given that in human
brain-derived synaptosomes, a recent study observed that phospho-
tau is increased in Ab-positive synaptosomes in early AD (Bilou-
sova et al., 2016), it is possible that at the time point studied here,
synapse loss had already reached its maximum level and thus it was
too late to see the potentially early effects of human tau expression.
Together, these data indicate that endogenous tau may play an
important role in the neurotoxicity of tau and Ab in mouse models
and that this role may be at earlier stages of the disease. As the data
do not refute the possibility that tau and Ab are on different path-
ways to synapse loss, a mouse model that expressed wild-type
human tau in the absence of mouse tau studied at multiple time
points would be beneﬁcial to studying the possible interaction
between these two important molecules in the context of human
AD and synapse loss.
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Fig. S1. Overexpression of human tau does not affect reactive astro-
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GAPDH (B) as a loading control. The GFAP band at 55 kDa was
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quantiﬁed and the overexpression of human tau did not change the
overall levels of GFAP (C). APP/PS1/rTg21221 n = 5, APP/
PS1n = 3.
Fig. S2. Overexpression of human tau does affect synapse protein
levels. Western blot of crude homogenates from mouse cortices
(5 lg protein) probed for (A) synaptophysin and (B) a-tubulin as a
loading control. The overexpression of human tau in APP/PS1 mice
did not change the levels of synaptophysin (C). APP/PS1/rTg21221
n = 5, APP/PS1 n = 4, rTg21221 n = 5.
Fig. S3. Overexpression of human tau does not affect protein levels
at the synapse. ELISA of synaptoneurosomes showed no difference
in Ab42 levels between APP/PS1 and APP/PS1/rTg21221 (A) Wes-
tern blot of synaptoneurosomes (5 lg protein) was probed for (B)
Ab (82E1) and (C) human tau (tau13) with b-actin as loading con-
trol. The overexpression of human tau did not change the amount of
Ab found in synaptoneurosome when comparing APP/PS1/
rTg21221 with APP/PS1 mice (D). Furthermore, Ab did not affect
the amount of human tau found in the synaptoneurosome when
comparing APP/PS1/rTg21221 with rTg21221 mice (E). APP/PS1/
rTg21221 n = 5, APP/PS1 n = 3, rTg21221 n = 4.
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